Xconomy National

Archives

by in
Entry Author Date Location
Seattle Genetics Sees Updated Side Effect Warning in Drug Label Luke Timmerman 01/13/12 Seattle
Xconomy Seattle’s Top 12 Life Sciences Stories of the Year Luke Timmerman 12/28/11 Seattle
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups Luke Timmerman 12/22/11 Seattle
Seattle Genetics, Millennium Look to Broaden Reach of Hodgkin’s Drug Luke Timmerman 12/09/11 Seattle
Scale Venture Partners Gives Up On Healthcare & Life Sciences Investing Wade Roush 11/08/11 San Francisco
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011 Luke Timmerman 11/07/11 National
Seattle Genetics Beats Expectations With $10M Sales in Lymphoma Drug Debut Luke Timmerman 11/03/11 Seattle
Analyst: Seattle Genetics on Pace to Smash Wall Street Forecast with Lymphoma Drug Rollout Luke Timmerman 10/20/11 Seattle
Fearless Fantasy Football, Uh, I Mean Biotech, Predictions for the Season Ahead Luke Timmerman 09/06/11 National
Seattle Genetics’ Market Debut, Pathway Gets Bought, Theraclone’s Latest Trick Against HIV, & More Seattle-Area Life Sciences News Luke Timmerman 08/25/11 Seattle
Video: Seattle Genetics CEO Makes the Case for a $100K Cancer Drug Luke Timmerman 08/22/11 Seattle
Seattle Genetics Sets Lymphoma Drug Price at $13,500 Per Dose Luke Timmerman 08/22/11 Seattle
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs Luke Timmerman 08/22/11 National
Seattle Genetics Wins FDA Approval of First Drug, a New Treatment for Lymphomas Luke Timmerman 08/19/11 Seattle
SeaGen Passes FDA Panel, Ken Stuart’s Journey to Seattle Biomed, the Latest M&A Obsession, & More Seattle-Area Life Sciences News Luke Timmerman 07/21/11 Seattle
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent Luke Timmerman 07/18/11 National
Seattle Genetics Lymphoma Drug Gets Second Green Light from FDA Panel Luke Timmerman 07/14/11 Seattle
Seattle Genetics Wins Unanimous OK for Lymphoma Drug from FDA Panel Luke Timmerman 07/14/11 Seattle
SeaGen’s Big Day at the FDA, Hutch Nabs $20M HIV Grant, Allozyne’s Nasdaq Plan, & More Seattle-Area Life Sciences News Luke Timmerman 07/14/11 Seattle
Insider Trader Pleads Guilty in SeaGen Case Luke Timmerman 07/12/11 Seattle
Seattle Genetics’ New ‘Empowered Antibody’ Looks Clean in FDA Staff Documents Luke Timmerman 07/12/11 Seattle
Seattle Genetics’ FDA Panel Preview: What You Need to Know This Week Luke Timmerman 07/12/11 Seattle
SeaGen Preserves Science Culture, Dendreon Sways Medicare, NanoString’s Financing, & More Seattle-Area Life Sciences News Luke Timmerman 07/07/11 Seattle
Seattle Genetics, On the Verge of Going Commercial, Seeks to Keep Its Scientific Soul Luke Timmerman 07/05/11 Seattle
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News Luke Timmerman 06/23/11 Seattle
Cyterix Develops New Twist on an Old Idea, With ‘Smart Bomb’ Cancer Drugs Luke Timmerman 06/22/11 San Francisco
SeaGen Promotes Dobmeier Luke Timmerman 06/17/11 Seattle
ASCO Wrap-Up, Pathway Medical Grinds It Out, Gates Foundation’s New Digs, & More in Seattle-Area Life Sciences News Luke Timmerman 06/09/11 Seattle
ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S. Luke Timmerman 06/07/11 National
Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News Luke Timmerman 05/19/11 Seattle
Page 1 of 7 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.